1282516-66-8

Basic information

• Product Name: 5-broMo-2-(1H-iMidazol-2-yl)phenol
• Synonyms: 5-broMo-2-(1H-iMidazol-2-yl)phenol
• CAS NO: 1282516-66-8
• Molecular Formula: C₉H₇BrN₂O
• Molecular Weight: 239.06868
• Mol File: 1282516-66-8.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-broMo-2-(1H-iMidazol-2-yl)phenol(CAS DataBase Reference)
• NIST Chemistry Reference: 5-broMo-2-(1H-iMidazol-2-yl)phenol(1282516-66-8)
• EPA Substance Registry System: 5-broMo-2-(1H-iMidazol-2-yl)phenol(1282516-66-8)

Safety Data

• Hazardous Substances Data: 1282516-66-8(Hazardous Substances Data)

Usage

Description

5-bromo-2-(1H-imidazol-2-yl)phenol is a phenolic compound characterized by the molecular formula C9H7BrN2O. It features a bromine atom and an imidazole ring, which contribute to its unique chemical properties. 5-broMo-2-(1H-iMidazol-2-yl)phenol is widely utilized in organic synthesis and pharmaceutical research, particularly for the development of drugs that target the central nervous system. Its diverse biological activities, including potential anti-inflammatory and anti-cancer properties, make it a valuable asset in medicinal chemistry and drug discovery.

Uses

Used in Pharmaceutical Research:
5-bromo-2-(1H-imidazol-2-yl)phenol is used as a key intermediate in the synthesis of various pharmaceutical compounds, particularly those targeting the central nervous system. Its unique structure allows for the development of drugs with potential therapeutic applications in treating neurological disorders and conditions.
Used in Organic Synthesis:
As a chemical compound with a bromine atom and an imidazole ring, 5-bromo-2-(1H-imidazol-2-yl)phenol is used as a versatile building block in organic synthesis. It can be employed in the preparation of a wide range of organic molecules, including those with potential applications in various industries.
Used in Drug Discovery:
5-bromo-2-(1H-imidazol-2-yl)phenol is used as a lead compound in drug discovery efforts. Its biological activities, such as potential anti-inflammatory and anti-cancer properties, make it a promising candidate for the development of novel therapeutic agents. Researchers can use this compound as a starting point to design and optimize new drugs with improved efficacy and safety profiles.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 5-bromo-2-(1H-imidazol-2-yl)phenol is used as a valuable tool for understanding the structure-activity relationships of various biologically active molecules. Its unique structural features can provide insights into the design of more effective and selective drugs, ultimately contributing to the advancement of pharmaceutical research.
Used in Anti-inflammatory and Anti-cancer Research:
5-bromo-2-(1H-imidazol-2-yl)phenol is used as a potential therapeutic agent in anti-inflammatory and anti-cancer research. Its biological activities suggest that it may have the ability to modulate inflammatory processes and inhibit the growth and progression of cancer cells. Further studies are needed to fully understand its mechanisms of action and optimize its potential as a treatment for these conditions.

Upstream product

• 591-20-8 3-Bromophenol 
• 131543-46-9 Glyoxal 
• 22532-62-3 4-bromosalicylaldehyde 

Downstream Products

• 2060571-02-8 (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide 
• 1282512-48-4 taselisib 
• 1401300-81-9 2-(2-(1-isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)benzenesulfonamide 
• 1282516-74-8 9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d]-[1,4]oxazepine-2-carboxylic acid 
• 1282516-68-0 9-bromo-2,3-diiodo-5,6-dihydrobenzo[f ]imidazo[1,2-d][1,4]oxazepine 

Relevant articles and documents

INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

An inhibitor containing a tricyclic derivative, a preparation method therefor and a pharmaceutical composition comprising the inhibitor, as well as a use thereof as a phosphoinositide 3 kinase (PI3K) inhibitor in the treatment of cancer and diseases or conditions mediated by or dependent on PI3K imbalance.

Manufacture of the PI3K β-Sparing Inhibitor Taselisib. Part 1: Early-Stage Development Routes to the Bromobenzoxazepine Core

Two convergent regioselective routes for the synthesis of the tetracyclic imidazobenzoxazepine triazole 1, a key intermediate toward the synthesis of taselisib, are described. In the first-generation route, a chemoselective Negishi cross-coupling reaction was developed between iodoimidazole 3 and triazole 7, which enabled the delivery of initial kilogram quantities of 1. Because of the inefficiencies in the preparation of the imidazole 3, a second-generation route via a highly regioselective imidazole ring formation between α-chloroketone 11 and aryl amidine 12 was developed. The resulting imidazole 14 provided the handle to efficiently install the seven-membered benzoxazepine ring system in one pot with two-step N-alkylation and SNAr tandem reactions.

BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE

Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.